Cargando…

GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients

INTRODUCTION: Glutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to chemotherapy in acute lymphoblastic leukemia (ALL). This case–control study investigated the association of GST gene polymor...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Shahid M., Pandith, Arshad A., Shah, Zafar A., Geelani, Sajad A., Bhat, Javid R., Gul, Ayaz, Guru, Sameer A., El-Serehy, Hamed A., Koul, Abid M., Mansoor, Sheikh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552530/
https://www.ncbi.nlm.nih.gov/pubmed/34722260
http://dx.doi.org/10.3389/fonc.2021.714421
_version_ 1784591393734262784
author Baba, Shahid M.
Pandith, Arshad A.
Shah, Zafar A.
Geelani, Sajad A.
Bhat, Javid R.
Gul, Ayaz
Guru, Sameer A.
El-Serehy, Hamed A.
Koul, Abid M.
Mansoor, Sheikh
author_facet Baba, Shahid M.
Pandith, Arshad A.
Shah, Zafar A.
Geelani, Sajad A.
Bhat, Javid R.
Gul, Ayaz
Guru, Sameer A.
El-Serehy, Hamed A.
Koul, Abid M.
Mansoor, Sheikh
author_sort Baba, Shahid M.
collection PubMed
description INTRODUCTION: Glutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to chemotherapy in acute lymphoblastic leukemia (ALL). This case–control study investigated the association of GST gene polymorphisms with the etiology and therapeutic outcome of B-ALL among Kashmiri population. METHODS: A total of 300 individuals including 150 newly diagnosed B-ALL patients and an equal number of age and gender matched controls were genotyped for five GST gene polymorphisms by polymerase chain reaction–restriction fragment length polymorphism technique (PCR-RFLP) and multiplex PCR techniques. RESULTS: Higher frequency of GSTT1 (null), GSTO2-AG, and GSTO2-GG genotypes was observed in ALL cases compared to controls that associated significantly with ALL risk (GSTT1 (null:) OR = 2.93, p = 0.0001; GSTO2-AG: OR = 2.58, p = 0.01; GSTO2-GG: OR = 3.13, p = 0.01). GSTM1, GSTP1, and GSTO1 SNPs showed no significant association (p > 0.05). Combined genotype analysis revealed significant association of GSTT1 (null)/GSTM1 (null) (OR = 4.11, p = 0.011) and GSTT1 (null)/GSTP1-AG (OR = 4.93, p = 0.0003) with B-ALL susceptibility. Haplotype analysis of rs4925 and rs156697 revealed that carriers of CG haplotype had increased risk of B-ALL (p = 0.04). Kaplan–Meier plots revealed significantly inferior 3-year disease-free survival for GSTO2-GG carriers (p = 0.002). Multivariate analysis confirmed GSTO2-GG as an independent poor prognostic factor for DFS (HR = 4.5, p = 0.034). Among combined genotypes, only GSTT1 (null)/GSTP1-AG associated significantly with poorer DFS rates (p = 0.032). CONCLUSION: This study demonstrated that GSTT1 (null) individually or in combination with GSTM1(null) and GSTP1-AG genotypes associated with increased B-ALL risk. Also, rs156697 variant genotypes (AG and GG) associated with B-ALL, whereas the GG genotype of rs156697 influenced the treatment outcome.
format Online
Article
Text
id pubmed-8552530
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85525302021-10-29 GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients Baba, Shahid M. Pandith, Arshad A. Shah, Zafar A. Geelani, Sajad A. Bhat, Javid R. Gul, Ayaz Guru, Sameer A. El-Serehy, Hamed A. Koul, Abid M. Mansoor, Sheikh Front Oncol Oncology INTRODUCTION: Glutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to chemotherapy in acute lymphoblastic leukemia (ALL). This case–control study investigated the association of GST gene polymorphisms with the etiology and therapeutic outcome of B-ALL among Kashmiri population. METHODS: A total of 300 individuals including 150 newly diagnosed B-ALL patients and an equal number of age and gender matched controls were genotyped for five GST gene polymorphisms by polymerase chain reaction–restriction fragment length polymorphism technique (PCR-RFLP) and multiplex PCR techniques. RESULTS: Higher frequency of GSTT1 (null), GSTO2-AG, and GSTO2-GG genotypes was observed in ALL cases compared to controls that associated significantly with ALL risk (GSTT1 (null:) OR = 2.93, p = 0.0001; GSTO2-AG: OR = 2.58, p = 0.01; GSTO2-GG: OR = 3.13, p = 0.01). GSTM1, GSTP1, and GSTO1 SNPs showed no significant association (p > 0.05). Combined genotype analysis revealed significant association of GSTT1 (null)/GSTM1 (null) (OR = 4.11, p = 0.011) and GSTT1 (null)/GSTP1-AG (OR = 4.93, p = 0.0003) with B-ALL susceptibility. Haplotype analysis of rs4925 and rs156697 revealed that carriers of CG haplotype had increased risk of B-ALL (p = 0.04). Kaplan–Meier plots revealed significantly inferior 3-year disease-free survival for GSTO2-GG carriers (p = 0.002). Multivariate analysis confirmed GSTO2-GG as an independent poor prognostic factor for DFS (HR = 4.5, p = 0.034). Among combined genotypes, only GSTT1 (null)/GSTP1-AG associated significantly with poorer DFS rates (p = 0.032). CONCLUSION: This study demonstrated that GSTT1 (null) individually or in combination with GSTM1(null) and GSTP1-AG genotypes associated with increased B-ALL risk. Also, rs156697 variant genotypes (AG and GG) associated with B-ALL, whereas the GG genotype of rs156697 influenced the treatment outcome. Frontiers Media S.A. 2021-10-14 /pmc/articles/PMC8552530/ /pubmed/34722260 http://dx.doi.org/10.3389/fonc.2021.714421 Text en Copyright © 2021 Baba, Pandith, Shah, Geelani, Bhat, Gul, Guru, El-Serehy, Koul and Mansoor https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Baba, Shahid M.
Pandith, Arshad A.
Shah, Zafar A.
Geelani, Sajad A.
Bhat, Javid R.
Gul, Ayaz
Guru, Sameer A.
El-Serehy, Hamed A.
Koul, Abid M.
Mansoor, Sheikh
GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients
title GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients
title_full GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients
title_fullStr GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients
title_full_unstemmed GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients
title_short GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients
title_sort gstt1 (null) and rs156697 polymorphism in gsto2 influence the risk and therapeutic outcome of b-acute lymphoblastic leukemia patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552530/
https://www.ncbi.nlm.nih.gov/pubmed/34722260
http://dx.doi.org/10.3389/fonc.2021.714421
work_keys_str_mv AT babashahidm gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT panditharshada gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT shahzafara gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT geelanisajada gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT bhatjavidr gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT gulayaz gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT gurusameera gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT elserehyhameda gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT koulabidm gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients
AT mansoorsheikh gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients